Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

National Research

BST:NR1A
Snowflake Description

Acceptable track record with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NR1A
BST
$1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • National Research has significant price volatility in the past 3 months.
NR1A Share Price and Events
7 Day Returns
0%
BST:NR1A
8.4%
DE Healthcare
9.9%
DE Market
1 Year Returns
10.8%
BST:NR1A
-25.6%
DE Healthcare
-17.5%
DE Market
NR1A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
National Research (NR1A) 0% -23.1% -36.1% 10.8% - -
DE Healthcare 8.4% -16.2% -21.1% -25.6% -43.3% -32%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • NR1A outperformed the Healthcare industry which returned -25.6% over the past year.
  • NR1A outperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
NR1A
Industry
5yr Volatility vs Market

NR1A Value

 Is National Research undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of National Research to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for National Research.

BST:NR1A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 4%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:NR1A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.657 (1 + (1- 21%) (3.23%))
0.782
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.8 * 5.44%)
3.96%

Discounted Cash Flow Calculation for BST:NR1A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for National Research is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BST:NR1A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 3.96%)
2020 36.02 Est @ 1.21% 34.65
2021 36.28 Est @ 0.73% 33.57
2022 36.43 Est @ 0.39% 32.42
2023 36.48 Est @ 0.16% 31.23
2024 36.48 Est @ -0.01% 30.04
2025 36.44 Est @ -0.12% 28.86
2026 36.36 Est @ -0.2% 27.70
2027 36.27 Est @ -0.26% 26.58
2028 36.16 Est @ -0.3% 25.49
2029 36.04 Est @ -0.33% 24.44
Present value of next 10 years cash flows $294.00
BST:NR1A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $36.04 × (1 + -0.39%) ÷ (3.96% – -0.39%)
$825.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $825.00 ÷ (1 + 3.96%)10
$559.38
BST:NR1A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $294.00 + $559.38
$853.38
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $853.38 / 24.94
$34.21
BST:NR1A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:NR1A represents 0.8383x of NasdaqGS:NRC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8383x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 34.21 x 0.8383
€28.68
Value per share (EUR) From above. €28.68
Current discount Discount to share price of €38.00
= -1 x (€38.00 - €28.68) / €28.68
-32.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of National Research is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for National Research's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are National Research's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:NR1A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $1.30
NasdaqGS:NRC Share Price ** NasdaqGS (2020-03-31) in USD $45.33
Germany Healthcare Industry PE Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 27.51x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of National Research.

BST:NR1A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NRC Share Price ÷ EPS (both in USD)

= 45.33 ÷ 1.30

34.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • National Research is overvalued based on earnings compared to the DE Healthcare industry average.
  • National Research is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does National Research's expected growth come at a high price?
Raw Data
BST:NR1A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 34.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.22x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for National Research, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on National Research's assets?
Raw Data
BST:NR1A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.32
NasdaqGS:NRC Share Price * NasdaqGS (2020-03-31) in USD $45.33
Germany Healthcare Industry PB Ratio Median Figure of 14 Publicly-Listed Healthcare Companies 1.13x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
BST:NR1A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NRC Share Price ÷ Book Value per Share (both in USD)

= 45.33 ÷ 1.32

34.27x

* Primary Listing of National Research.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • National Research is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess National Research's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. National Research has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NR1A Future Performance

 How is National Research expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as National Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.4%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is National Research expected to grow at an attractive rate?
  • Unable to compare National Research's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare National Research's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare National Research's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:NR1A Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 9.4%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:NR1A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:NR1A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:NR1A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 128 41 32
2019-09-30 126 43 31
2019-06-30 124 38 30
2019-03-31 120 39 31
2018-12-31 120 40 30
2018-09-30 119 33 29
2018-06-30 118 36 26
2018-03-31 118 28 24
2017-12-31 118 28 23
2017-09-30 116 30 22
2017-06-30 114 26 23
2017-03-31 112 31 21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if National Research is high growth as no earnings estimate data is available.
  • Unable to determine if National Research is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:NR1A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from National Research Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:NR1A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:NR1A Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 1.30
2019-09-30 1.22
2019-06-30 1.14
2019-03-31 1.13
2018-12-31 1.11
2018-09-30 1.10
2018-06-30 1.03
2018-03-31 0.97
2017-12-31 0.94
2017-09-30 0.91
2017-06-30 0.93
2017-03-31 0.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if National Research will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of NR1A’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. National Research's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. National Research's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess National Research's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
National Research has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NR1A Past Performance

  How has National Research performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare National Research's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • National Research's year on year earnings growth rate has been positive over the past 5 years.
  • National Research's 1-year earnings growth is less than its 5-year average (7.8% vs 14.8%)
  • National Research's earnings growth has not exceeded the DE Healthcare industry average in the past year (7.8% vs 26%).
Earnings and Revenue History
National Research's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from National Research Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:NR1A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 127.98 32.30 32.95
2019-09-30 126.00 31.41 32.57
2019-06-30 123.55 30.29 31.54
2019-03-31 120.15 30.84 31.16
2018-12-31 119.69 29.95 31.32
2018-09-30 118.95 28.64 31.15
2018-06-30 117.88 25.79 31.90
2018-03-31 118.30 23.58 30.87
2017-12-31 117.56 22.77 29.69
2017-09-30 116.03 21.98 28.64
2017-06-30 114.11 22.54 27.35
2017-03-31 111.79 21.35 27.71
2016-12-31 109.38 20.34 28.39
2016-09-30 107.38 20.52 28.06
2016-06-30 105.59 19.95 27.54
2016-03-31 103.94 19.46 26.91
2015-12-31 102.34 17.46 27.18
2015-09-30 101.10 15.70 27.70
2015-06-30 99.54 16.14 26.88
2015-03-31 99.08 16.16 26.23
2014-12-31 98.84 18.16 24.97
2014-09-30 96.64 17.82 24.46
2014-06-30 95.36 17.09 24.67
2014-03-31 93.71 16.47 25.08
2013-12-31 92.59 15.48 25.21
2013-09-30 91.66 15.42 24.90
2013-06-30 90.64 15.18 24.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst National Research made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • National Research used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • National Research has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess National Research's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
National Research has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NR1A Health

 How is National Research's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up National Research's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • National Research's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • National Research's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of National Research's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from National Research Company Filings, last reported 3 months ago.

BST:NR1A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 32.89 34.17 13.52
2019-09-30 28.98 35.11 8.36
2019-06-30 25.97 37.03 4.02
2019-03-31 22.74 38.69 2.64
2018-12-31 19.08 37.84 12.99
2018-09-30 30.14 38.73 7.27
2018-06-30 26.82 39.60 6.70
2018-03-31 95.36 0.00 35.48
2017-12-31 90.04 1.07 34.73
2017-09-30 88.84 1.69 35.75
2017-06-30 87.83 2.11 31.63
2017-03-31 85.57 2.72 34.66
2016-12-31 82.81 3.54 33.02
2016-09-30 81.23 3.95 28.88
2016-06-30 79.66 4.55 27.19
2016-03-31 76.17 5.15 25.37
2015-12-31 74.22 5.74 42.15
2015-09-30 86.59 6.33 37.58
2015-06-30 89.70 6.91 40.56
2015-03-31 87.84 7.49 37.01
2014-12-31 87.75 8.07 40.04
2014-09-30 86.31 8.64 39.06
2014-06-30 82.08 9.20 31.54
2014-03-31 77.32 9.77 26.45
2013-12-31 71.76 10.32 22.09
2013-09-30 67.54 10.88 18.93
2013-06-30 63.24 11.61 10.80
  • National Research's level of debt (103.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (9% vs 103.9% today).
  • Debt is well covered by operating cash flow (119.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 21x coverage).
X
Financial health checks
We assess National Research's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. National Research has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NR1A Dividends

 What is National Research's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.85%
Current annual income from National Research dividends.
If you bought €2,000 of National Research shares you are expected to receive €37 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • National Research's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.68%).
  • National Research's dividend is below the markets top 25% of dividend payers in Germany (4.97%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:NR1A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:NR1A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
BST:NR1A Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2020-03-09 0.840 1.933
2019-11-25 0.840 1.290
2019-11-08 0.760 1.229
2019-06-03 0.760 1.288
2019-02-13 0.760 1.844
2018-12-10 0.760 1.947
2018-09-04 0.680 1.772
2018-06-01 0.680 1.813
2018-05-04 0.400 1.160
2018-05-01 0.400 1.149
2018-02-20 2.400 7.661
2018-02-13 0.400 1.228
2017-12-07 2.400 6.657
2017-11-09 0.400 1.195
2017-11-07 0.400 1.196
2017-09-01 2.400 6.596
2017-08-04 0.400 1.300
2017-08-01 0.400 1.344
2017-05-16 2.400 8.988
2017-05-05 0.400 1.647
2017-03-03 0.400 1.944
2017-02-14 0.400 2.173
2016-11-09 2.400 13.630
2016-11-04 0.320 2.026
2016-11-01 0.320 2.147
2016-08-30 1.920 12.122
2016-08-05 0.320 1.975
2016-05-06 0.320 2.250
2016-03-04 0.320 2.173
2016-02-10 0.320 2.174
2015-12-01 1.920 12.624
2015-11-05 0.240 1.551
2015-11-03 0.240 1.535
2015-08-27 1.440 10.907
2015-08-06 0.240 1.854
2015-08-04 0.240 1.801
2015-06-09 1.440 10.183
2015-05-08 0.240 1.716
2015-05-07 0.240 1.687
2015-03-09 1.440 9.968
2014-12-09 1.440 10.327
2014-11-07 0.000 0.000
2014-11-04 0.000 0.000
2014-08-06 0.000 0.000
2014-08-05 0.000 0.000
2014-05-08 0.000 0.000
2014-05-06 0.000 0.000
2014-03-04 0.000 0.000
2014-02-11 0.000 0.000
2013-11-07 0.000 0.000
2013-11-06 0.000 0.000
2013-08-08 0.000 0.000
2013-08-06 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • National Research has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • National Research has only been paying a dividend for 5 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of National Research's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess National Research's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can National Research afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. National Research has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NR1A Management

 What is the CEO of National Research's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Hays
COMPENSATION $289,467
AGE 64
TENURE AS CEO 39.3 years
CEO Bio

Mr. Michael D. Hays, also known as Mike, serves as an Advisor of Picker Institute Inc. Mr. Hays founded National Research Corp. in 1981 and has been its Chief Executive Officer since 1981. Mr. Hays served as the President of National Research Corp. from July 10, 2008 to July 5, 2011 and from 1981 to 2004. Mr. Hays served as Senior Vice President of Investments and International Operations of Massachusetts Mutual Life Insurance Co. Mr. Hays served for seven years as a Vice President and a Director of SRI Research Center, Inc. (n/k/a the Gallup Organization). He serves as a Director of National Research Corp. since 1981. Mr. Hays served as Director of Nebraska Global Investment Company, LLC.

CEO Compensation
  • Mike's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Mike's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the National Research management team in years:

6.5
Average Tenure
61
Average Age
  • The average tenure for the National Research management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Hays

TITLE
Founder
COMPENSATION
$289K
AGE
64
TENURE
39.3 yrs

Steve Jackson

TITLE
President
COMPENSATION
$677K
AGE
43
TENURE
4.5 yrs

Kevin Karas

TITLE
Senior VP of Finance
COMPENSATION
$645K
AGE
61
TENURE
8.6 yrs

Helen Hrdy

TITLE
Senior Vice President of Client Services
TENURE
4.3 yrs

Linda Stacy

TITLE
Vice President of Finance
Board of Directors Tenure

Average tenure and age of the National Research board of directors in years:

7.9
Average Tenure
66
Average Age
  • The tenure for the National Research board of directors is about average.
Board of Directors

Mike Hays

TITLE
Founder
COMPENSATION
$289K
AGE
64
TENURE
39.3 yrs

JoAnn Martin

TITLE
Independent Director
COMPENSATION
$150K
AGE
64
TENURE
18.8 yrs

Barbara Mowry

TITLE
Independent Director
COMPENSATION
$150K
AGE
71
TENURE
5.9 yrs

Don Berwick

TITLE
Independent Director
COMPENSATION
$150K
AGE
72
TENURE
4.5 yrs

John Nunnelly

TITLE
Lead Director
COMPENSATION
$175K
AGE
66
TENURE
7.9 yrs
Who owns this company?
Recent Insider Trading
  • National Research individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Feb 20 Sell Michael Hays Individual 14. Feb 20 14. Feb 20 -3,000 €64.66 €-193,989
10. Feb 20 Sell Michael Hays Individual 06. Feb 20 07. Feb 20 -1,800 €64.17 €-115,440
06. Feb 20 Sell Michael Hays Individual 04. Feb 20 04. Feb 20 -22,160 €63.55 €-1,408,372
04. Feb 20 Sell Michael Hays Individual 31. Jan 20 31. Jan 20 -21,350 €63.21 €-1,349,587
30. Jan 20 Sell Michael Hays Individual 28. Jan 20 28. Jan 20 -9,252 €63.63 €-588,695
28. Jan 20 Sell Michael Hays Individual 24. Jan 20 27. Jan 20 -5,644 €63.60 €-358,924
24. Jan 20 Sell Michael Hays Individual 22. Jan 20 23. Jan 20 -7,830 €63.50 €-496,976
24. Jan 20 Sell Steven Jackson Individual 04. Oct 19 04. Oct 19 -4,010 €53.89 €-216,085
14. Jan 20 Sell Michael Hays Individual 10. Jan 20 10. Jan 20 -200 €61.17 €-12,235
10. Jan 20 Sell Michael Hays Individual 08. Jan 20 09. Jan 20 -6,276 €61.41 €-385,277
08. Jan 20 Sell Michael Hays Individual 06. Jan 20 07. Jan 20 -8,622 €61.38 €-528,669
26. Dec 19 Sell Michael Hays Individual 23. Dec 19 23. Dec 19 -10,000 €61.37 €-613,697
04. Dec 19 Sell Michael Hays Individual 02. Dec 19 02. Dec 19 -1,400 €57.67 €-80,733
02. Dec 19 Sell Michael Hays Individual 27. Nov 19 29. Nov 19 -7,453 €58.10 €-432,789
27. Nov 19 Sell Michael Hays Individual 25. Nov 19 26. Nov 19 -5,941 €58.17 €-345,057
25. Nov 19 Sell Michael Hays Individual 21. Nov 19 22. Nov 19 -1,800 €58.27 €-104,254
20. Sep 19 Sell Michael Hays Individual 19. Sep 19 19. Sep 19 -6,200 €57.14 €-354,297
21. Nov 19 Sell Barbara Mowry Individual 19. Nov 19 20. Nov 19 -14,785 €56.66 €-834,902
19. Nov 19 Sell Barbara Mowry Individual 15. Nov 19 18. Nov 19 -3,215 €55.88 €-179,357
15. Nov 19 Sell Barbara Mowry Individual 13. Nov 19 14. Nov 19 -7,762 €56.08 €-435,123
26. Sep 19 Sell Steven Jackson Individual 25. Sep 19 25. Sep 19 -4,000 €55.50 €-222,001
23. Sep 19 Sell Steven Jackson Individual 20. Sep 19 20. Sep 19 -2,500 €57.44 €-143,606
20. Sep 19 Sell Steven Jackson Individual 19. Sep 19 19. Sep 19 -380 €57.46 €-21,835
19. Sep 19 Sell Steven Jackson Individual 18. Sep 19 18. Sep 19 -2,500 €56.04 €-140,105
19. Sep 19 Sell Michael Hays Individual 18. Sep 19 18. Sep 19 -500,000 €54.69 €-27,344,828
18. Sep 19 Sell Donald Berwick Individual 17. Sep 19 17. Sep 19 -6,992 €56.07 €-392,044
18. Sep 19 Sell Steven Jackson Individual 17. Sep 19 17. Sep 19 -2,500 €56.08 €-140,198
17. Sep 19 Sell Donald Berwick Individual 16. Sep 19 16. Sep 19 -6,989 €56.41 €-394,257
16. Sep 19 Sell Donald Berwick Individual 13. Sep 19 13. Sep 19 -2,924 €55.98 €-163,677
13. Sep 19 Sell Donald Berwick Individual 12. Sep 19 12. Sep 19 -1,120 €56.13 €-62,868
09. Sep 19 Sell Kevin Karas Individual 06. Sep 19 06. Sep 19 -2,902 €56.86 €-165,016
09. Sep 19 Sell Donald Berwick Individual 06. Sep 19 06. Sep 19 -9,035 €57.03 €-515,221
06. Sep 19 Sell Kevin Karas Individual 05. Sep 19 05. Sep 19 -7,114 €58.24 €-411,870
04. Sep 19 Sell Michael Hays Individual 03. Sep 19 03. Sep 19 -33,800 €59.13 €-1,998,689
05. Sep 19 Sell Michael Hays Individual 04. Sep 19 04. Sep 19 -1,063 €58.82 €-62,521
30. Aug 19 Sell Michael Hays Individual 29. Aug 19 29. Aug 19 -2,800 €58.67 €-164,278
23. Aug 19 Sell Michael Hays Individual 21. Aug 19 22. Aug 19 -12,648 €58.47 €-739,476
21. Aug 19 Sell Michael Hays Individual 20. Aug 19 20. Aug 19 -900 €58.16 €-52,344
19. Aug 19 Sell Michael Hays Individual 16. Aug 19 16. Aug 19 -3,763 €58.35 €-219,553
16. Aug 19 Sell Michael Hays Individual 14. Aug 19 15. Aug 19 -19,000 €58.51 €-1,107,442
29. Aug 19 Sell Michael Hays Individual 28. Aug 19 28. Aug 19 -252,000 €56.84 €-14,323,714
X
Management checks
We assess National Research's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. National Research has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NR1A News

Simply Wall St News

NR1A Company Info

Description

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions; and risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Details
Name: National Research Corporation
NR1A
Exchange: BST
Founded: 1981
$1,032,340,461
24,943,713
Website: http://nrchealth.com
Address: National Research Corporation
1245 Q Street,
Lincoln,
Nebraska, 68508,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NRC Common Stock Nasdaq Global Select US USD 20. May 2013
BST NR1A Common Stock Boerse-Stuttgart DE EUR 20. May 2013
Number of employees
Current staff
Staff numbers
472
National Research employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/01 03:10
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2019/02/12
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.